Mar 8, 2019
In Part 1, we look at the original studies that led to the
discovery of TNF in two separate labs where researchers were
looking for two completely different things. We’ll learn how these
discoveries then fueled the use of TNF in the failed trials as an
anti-cancer agent, and the eventual development of antibody therapy
against TNF in septic shock.
- Intro :11
- The origins of this episode and what we’ll cover here and in
Part 2 :18
- What Part 1 will cover 2:01
- Early cytokine research in general
- codiscovery of TNF
- TNF as anticancer agent
- TNF’s role in cachexia
- trials of anti-TNF in the setting of septic shock
- What part 2 will cover 2:59
- TNF’s role in rheumatoid arthritis
- TNF in the late 1800s 3:18
- Lipopolysaccharide from gram-negative bacteria is first
isolated and discovered 8:16
- Fast forward to the 1960s, enter Memorial Sloan Kettering
Cancer Center 9:08
- Anthony Cerami studies cachexin in his Rockefeller lab
11:10
- Late 1980s: TNF is produced and given to humans using
recombinant technology 20:01
- Studies of TNF in patients with various types of cancer
20:48
- High doses seem to induce shock-like illness
21:38
- TNF-secreting tumor is created and tested
25:21
- Some take away 26:12
- Studying TNF led to the discovery that it’s associated with
shock 26:33
- Money pours into research on blocking TNF
27:00
- A look at studies of TNF in infection
27:22
- Study of TNF in sepsis 30:20
- Let’s talk about anti-TNF and what it’s doing
34:00
- Studies of anti-TNF in humans
36:00
- Rat and baboon studies don’t always correlate with humans
40:25
- Episode recap 40:45
- Stay tuned for Part 2 42:20
- Follow us on Twitter @HRheuminations and leave us a review in
iTunes 42:50
We’d love to hear from you! Send your comments/questions to
rheuminationspodcast@healio.com.
Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum
References:
Beutler B, et al. Science. 1985;229:869–871.
Blick M, et al. Cancer Research.
1987;47:2986-2989.
Carswell E,
Williamson B. Cancer Imm. 2012;12:4.
Feldman
M. Nat Rev Immunol. 2002;2:364-371.
Fong Y, et
al. J Exp Med. 1989;170:1627-1633.
Kawakami M.
Mol Med. 2014;doi:10.2119/molmed.2014.00177.
Lv S, et
al. Int J Clin Pract. 2014;68:520-528.
Marks
JD, et al. Am Rev Respir Dis. 1990;141:94-97.
McCarthy
EF. Iowa Orthop J. 2006;26:154-158.
Michi HR,
et al. N Engl J Med. 1988;318:1481-1486.
Oliff A. Cell. 1988;54:141-142.
Opal SM,
et al. J Infect Dis. 1990;161:1148-1152.
Qui P, et
al. Expert Opin Investig Drugs. 2011;20:1555-1564.
Tracey KJ,
et al. Nature. 1987;330:662-4.
Waage A,
et al. Lancet. 1987;1:355-7.